Skip to content

Search

New childhood brain tumour drugs to be tested

It is the kids he treats in his role as a paediatric oncologist that motivate Dr Nick Gottardo in his work as a The Kids Research Institute Australia cancer researcher.

Dad’s Dream Inspires Global Cancer Fight

The Global Symposium on Childhood Brain Tumours is bringing the world's premier childhood brain tumour researchers and scientists together in Perth.

Research sheds new light on childhood Leukaemia treatment

A The Kids study examining drug resistance in leukaemia patients has shed new light on why some treatments may be more effective than others.

Global Assault on Childhood Brain Tumours Gains Momentum

A report outlining key steps to tackle a common and aggressive childhood brain tumor is gaining rapid momentum after attracting international attention.

Ethan's brain cancer battle inspires research

A new research scholarship to combat childhood brain tumours will be launched tonight in honour of two year old Perth toddler Ethan Davies.

Researchers find genetic clue to cancer relapse

Cancer researchers at The Kids for Child Health Research have developed a new test that can rapidly detect the loss of genes in cancer cells.

Exposure to diagnostic radiological procedures and the risk of childhood acute lymphoblastic leukemia

Diagnostic irradiation of the mother during pregnancy increases the risk of childhood acute lymphoblastic leukemia

West Coast Cancer Meeting 2025

Join us as WA’s cancer research community comes together at the inaugural West Coast Cancer Meeting.

The health-related quality of life of lung cancer patients with EGFR-The Kids-related skin adverse drug reactions and its relationship with coping style and self-management

The status and associated factors of the health-related quality of life of non-small-cell lung cancer patients under targeted anti-cancer therapy have not been investigated. Self-management and coping style have been proven to be closely related to patients’ health-related quality of life.

Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin

Doxorubicin is the most frequently used chemotherapeutic agent for the treatment of hepatocellular carcinoma. However, one major obstacle to the effective management of liver cancer is the drug resistance derived from the cancer stem cells.